Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 233,201,863 papers from all fields of science
Search
Sign In
Create Free Account
eniluracil
Known as:
5-ethynyl-2,4(1H,3H)-Pyrimidinedione
, 2,4(1H,3H)-Pyrimidinedione, 5-ethynyl-
, ethynyluracil
Expand
An orally-active fluoropyrimidine analogue. Eniluracil inhibits dihydropyrimidine dehydrogenase, the rate-limiting enzyme that catabolizes and…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
7 relations
Dihydropyrimidine dehydrogenase
analogs & derivatives
ethynyluracil/fluorouracil
Broader (2)
Enzyme Inhibitors
Uracil
Narrower (2)
GW776
GW776C85
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
A possible cause and remedy for the clinical failure of 5-fluorouracil plus eniluracil.
T. Spector
,
Shousong Cao
Clinical colorectal cancer
2010
Corpus ID: 32019047
BACKGROUND Eniluracil is a potent inactivator of dihydropyrimidine dehydrogenase (uracil reductase), the enzyme that rapidly…
Expand
2003
2003
Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer
M. Heslin
,
Jieming Yan
,
+4 authors
R. Diasio
Cancer Chemotherapy and Pharmacology
2003
Corpus ID: 32198208
PurposeCatabolism of 5-fluorouracil (5-FU) is primarily regulated by DPD. Inactivation of DPD using eniluracil is advantageous in…
Expand
2003
2003
Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889
M. Endo
,
M. Miwa
,
+8 authors
H. Ishitsuka
International Journal of Cancer
2003
Corpus ID: 25367316
Capecitabine is an orally available fluoropyrimidine and is finally converted to 5‐FU selectively in tumor tissues. In our study…
Expand
2002
2002
Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
A. Adjei
,
J. Reid
,
+10 authors
C. Erlichman
Journal of Clinical Oncology
2002
Corpus ID: 40602489
PURPOSE To compare the pharmacokinetics of continuous venous infusion (CVI) fluorouracil (5-FU) with that of oral eniluracil/5-FU…
Expand
2002
2002
Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer.
J. Marsh
,
P. Catalano
,
+4 authors
A. Benson
Clinical colorectal cancer
2002
Corpus ID: 35760093
Coadministration of eniluracil with 5-fluorouracil (5-FU) allows the oral absorption of small doses of 5-FU, resulting in…
Expand
2002
2002
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil
D. Shepard
,
S. Mani
,
+8 authors
M. Ratain
Cancer Chemotherapy and Pharmacology
2002
Corpus ID: 8692848
Abstract.Aims: To determine the effect of food on the pharmacokinetics of 5-fluoruracil (5-FU) taken orally with eniluracil and…
Expand
Review
2000
Review
2000
Pharmacology of Fluorinated Pyrimidines: Eniluracil
S. Baker
Investigational new drugs
2000
Corpus ID: 20386666
The pharmacological inactivation of dihydropyrimidine dehydrogenase (DPD)represents one strategy to improve 5-FU therapy, which…
Expand
1999
1999
In vivo effect of 5-ethynyluracil on 5-fluorouracil metabolism determined by 19F nuclear magnetic resonance spectroscopy.
E. Adams
,
J. Leffert
,
D. J. Craig
,
T. Spector
,
G. Pizzorno
Cancer Research
1999
Corpus ID: 18540492
Biochemical modulation of 5-fluorouracil (5-FU) has been used over the past 20 years to improve the therapeutic efficacy of this…
Expand
Review
1998
Review
1998
New drugs in the treatment of colorectal carcinoma
C. Punt
Cancer
1998
Corpus ID: 25535882
Treatment with 5‐fluorouracil (5‐FU) plus leucovorin has been the unofficial standard therapy for patients with colorectal…
Expand
1995
1995
5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
Shousong Cao
,
D. Baccanari
,
S. Joyner
,
Stephen T. Davis
,
Y. Rustum
,
Thomas Spector
Cancer Research
1995
Corpus ID: 27999122
We studied the effects of 5-ethynyluracil (776C85 and 776C), a potent mechanism-based inactivator of dihydropyrimidine…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE